Association of diabetes susceptibility gene Calpain-10 with pancreatic cancer among smokers

Journal of Gastrointestinal Cancer

Volumn 41, Issue 3, 2010, Pages 203-208

  Fong, Pui Yee ^a   Fesinmeyer, Megan D ^b   White, Emily ^a,b   Farin, Federico M ^a   Srinouanprachanh, Sengkeo ^a   Afsharinejad, Zahra ^a   Mandelson, Margaret T ^b,d   Brentnall, Teresa A ^c   Barnett, Matt J ^b   Goodman, Gary E ^b   Austin, Melissa A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Calpain 10; CAPN10; Diabetes; Pancreatic cancer

Indexed keywords

ASBESTOS; CALPAIN 10;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DIABETES MELLITUS; DNA EXTRACTION; EXPOSURE; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; SMOKING;

AGED; CALPAIN; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMOKING;

EID: 78149465869     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9130-7     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Fesinmeyer M, Austin M, Li C, De Roos A, Bowen D. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766-73.
3. Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M, Comparative Risk Assessment collaborating g. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005;366:1784-93.
4. Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer. 2009;8:109-17.
5. Eberle M, Pfützer R, Pogue-Geile K, et al. A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet. 2002;70:1044-8.
6. Pogue-Geile K, Chen R, Bronner M, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med. 2006;3:e516.
7. Ohnami S, Sato Y, Yoshimura K, et al. His595Tyr polymorphism in the methionine synthase reductase (MTRR) gene is associated with pancreatic cancer risk. Gastroenterology. 2008;135:477-88.
8. Asomaning K, Reid AE, Zhou W, et al. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res. 2008;14:4010-5.
9. Yang M, Sun T, Wang L, et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res. 2008;14:3230-6.
10. Cowgill S, Muscarella P. The genetics of pancreatic cancer. Am J Surg. 2003;186:279-86.
11. Huxley R, Ansary-Moghaddam A, de Berrington González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076-83.
12. Wang F, Gupta S, Holly E. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev. 2006;15:1458-63.
13. Chari S, Leibson C, Rabe K, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95-101.
14. Gapstur S, Gann P, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000;283:2552-8.
15. Horikawa Y, Oda N, Cox N, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000;26:163-75.
16. Marshall C, Hitman G, Partridge C, et al. Evidence that an isoform of calpain-10 is a regulator of exocytosis in pancreatic beta-cells. Mol Endocrinol. 2005;19:213-24.
17. Jensen D, Urhammer S, Eiberg H, et al. Variation in CAPN10 in relation to type 2 diabetes, obesity and quantitative metabolic traits: studies in 6018 whites. Mol Genet Metab. 2006;89:360-7.
18. Tsuchiya T, Schwarz P, Bosque-Plata L, et al. Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol Genet Metab. 2006;89:174-84.
19. Fesinmeyer MD, Standford JL, Brentnall TA, et al. Association between the Peroxisome proliferator-activated receptor-gamma Pro12Ala variant and haplotype and pancreatic cancer in a highrisk cohort of smokers: a pilot study. Pancreas. 2009;38(6):631-7.
20. Omenn G, Goodman G, Thornquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res. 1994;54:2038s-43.
21. Barrett J, Fry B, Maller J, Daly M. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-5.
22. Lin P, Vance J, Pericak-Vance M, Martin E. No gene is an island: the flip-flop phenomenon. Am J Hum Genet. 2007;80:531-8.
23. Zhou Y, Sreenan S, Pan C, et al. A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. Metabolism. 2003;52:528-34.
24. Johnson J, Han Z, Otani K, et al. RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J Biol Chem. 2004;279:24794-802.